VisionWave Holdings, Inc. filed a Form 8-K on November 12, 2026, disclosing that it entered into a non-binding Letter of Intent on November 9, 2026, to acquire a 51% participatory interest in EUROPOSTACHSERVICE LLC, a Ukrainian unmanned aerial systems company, for $7,000,000 in cash.
GT Biopharma, Inc. filed a Form 8-K on November 12, 2026, reporting the results of a Special Meeting of Stockholders held on November 11, 2026, at which four proposals were submitted to a vote.
Clarivate Plc filed a Form 8-K on November 12, 2026, announcing the expiration and results of cash tender offers by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for certain of its debt securities.
Agassi Sports Entertainment Corp. filed a Form 8-K on November 12, 2026, reporting agreements dated November 5, 2026, under which the company agreed to issue 300,000 shares of restricted common stock to Sinclair Television Group, Inc. and The Tennis Channel, LLC in exchange for …
HeartCore Enterprises, Inc. filed a Form 8-K on November 12, 2026, disclosing under Regulation FD that it had entered into a non-exclusive business development and sales agency agreement in Japan with ONE AI Co., Ltd.
M2i Global, Inc. filed a Form 8-K on November 12, 2026, disclosing that on November 6, 2026, it entered into a Membership Interest Purchase Agreement to acquire all outstanding interests in Graphex Technologies LLC for an aggregate purchase price of $100,000,000.
NextTrip, Inc. filed a Form 8-K on November 12, 2026, disclosing an expansion of its cruise strategy that links cruise-focused programming on JOURNY TV with digital booking tools and travel advisor support through Five Star Alliance.
VolitionRx Limited filed a Form 8-K on November 12, 2026, disclosing that Chief Executive Officer and President Cameron Reynolds agreed to an additional temporary reduction in his annual base salary, effective November 1, 2026, as part of the company's cost reduction measures.
DeFi Development Corp. filed a Form 8-K on November 12, 2026, reporting that its Board of Directors appointed Chief Financial Officer Fei (John) Han to also serve as Chief Operating Officer, effective November 9, 2026.
Neuronetics, Inc. filed a Form 8-K on November 12, 2026, disclosing that it entered into an Underwriting Agreement on November 10, 2026, to sell 18,750,000 shares of common stock at $1.60 per share, with expected net proceeds of approximately $27.7 million.